Aims: A suitable cut-off value for p53 overexpression and its usefulness as a prognostic factor in luminal/HER2-negative breast cancer were evaluated.
Patients And Methods: A retrospective analysis of 1,987 patients with luminal/HER2-negative breast cancer who underwent surgery between 2001 and 2009 was performed.
Results: p53 expression ≥50% was present in 9% of the patients. Moreover, these patients had significantly lower estrogen/progesterone receptor-positive rates, higher Ki-67 values, larger tumors, disease-positive nodes, higher nuclear grade, and shorter disease-free survival than patients with p53 expression <50% (p<0.0001). Therefore, status of p53-positive cells ≥50% was classified as p53 overexpression. These findings indicate that p53 overexpression is associated with unfavorable characteristics and prognosis.
Conclusion: The suitable cut-off value for p53 overexpression was determined to be 50%, and p53 overexpression appears to be a significant prognostic factor in patients with luminal/HER2-negative breast cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Time from Final Oncologist Visit to Death and Palliative Systemic Treatment Use Near the End of Life in Heavily Pretreated Patients with Luminal Breast Cancer.
J Clin Med
November 2024
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, 31-115 Krakow, Poland.
Article Synopsis
- Palliative care for patients with hormone receptor-positive, HER2-negative advanced breast cancer should be individualized, especially regarding when to stop treatment, as evidenced by a study assessing the time between last oncologist visit and death.
- The study involved 76 women, with a median age of about 63, who had received multiple lines of palliative treatment; surprisingly, 75% were still on active treatment during their last oncologist visit.
- Findings indicated a median of 23 days from the last visit to death, with the timing of ceasing systemic therapy often delayed, highlighting the need for improved end-of-life care guidelines and training for healthcare providers.
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.
Clin Cancer Res
September 2024
German Breast Group, Neu-Isenburg, Germany.
Purpose: The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens.
Experimental Design: We investigated PIK3CA mutations in 1,691 patients with early breast cancer who were randomized into four neoadjuvant multicenter trials: GeparQuattro (NCT00288002), GeparQuinto (NCT00567554), GeparSixto (NCT01426880), and GeparSepto (NCT01583426).
Serum miR-181а and miR-25 Levels in Patients with Breast Cancer or Benign Breast Disease.
Dokl Biochem Biophys
October 2023
Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia.
Circulating miR-181а and miR-25, which reflect regulation of the expression of carcinogenesis-related genes, were assayed in patients with invasive carcinoma of no specific type (ICNT) or benign breast diseases (BBDs) and in subjects without pathologies of the mammary gland (controls). miR-181а expression level proved to be higher compared to control in patients with fibroadenoma and adenosis with low, but not high, risk of malignant transformation, as well as in patients with luminal HER2-negative type B (Lum B HER2-), HER2-positive type (HER2+), and triple-negative breast cancer (TNBC) than in the controls and luminal-type (Lum A) breast cancer. MiR-25 expression level prevailed in patients with Lum B HER2- compared to control, Lum A, and TNBC patients compared to Lum A.
View Article and Find Full Text PDFAI-enabled routine H&E image based prognostic marker for early-stage luminal breast cancer.
NPJ Precis Oncol
November 2023
Tissue Image Analytics Centre, Department of Computer Science, University of Warwick, Coventry, UK.
Breast cancer (BC) grade is a well-established subjective prognostic indicator of tumour aggressiveness. Tumour heterogeneity and subjective assessment result in high degree of variability among observers in BC grading. Here we propose an objective Haematoxylin & Eosin (H&E) image-based prognostic marker for early-stage luminal/Her2-negative BReAst CancEr that we term as the BRACE marker.
View Article and Find Full Text PDFRelationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer.
Anticancer Res
November 2023
Department of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Background/aim: Everolimus (EVE)-based treatment is an option for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), but a predictive marker has not yet been established. The recommended dose of EVE in combination with endocrine therapy is 10 mg/day, but due to adverse effects, patients are frequently forced to reduce the dose. However, the correct maintenance dose to achieve a therapeutic effect is still under debate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!